OncoSignal
Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:31 UTC. Every row links to its source record.

Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time

HER2 Molecular Imaging With 89Zr-trastuzumab PET/CT as a Predictive Biomarker for Antibody-drug Conjugate Sequencing in Patients With Advanced HER2-positive Breast Cancer

NCT06595563 · Jules Bordet Institute · PHASE2 · terminated · last registry update 2026-08-20 · Breast cancer · Decision brief

No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.

What was said, and by whom

Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.

KindQuoteOur categorySource
Stated“Study logistics or limited study population, as defined by the iclusion/exclusion criteria, leading to a poor recruitment”–Registry record, Jules Bordet Institute

Also happening at the time. Not shown to be a cause.

Registry events on other trials of drugs against ERBB2 in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.

What is not public

  • Internal portfolio and board discussions
  • Unpublished trial data and interim analyses
  • Terms of any partner or licence decision